Developing obesity therapies based on a newly discovered pathway connecting hormone receptors on the tongue directly to the brain's satiety centers. With topical lingual application of PYY, we showed a strong satiety response in mice - as much as a large meal or an injection of the hormone, reduced acute food intake, and weight loss of 23%, with no systemic absorption and no tolerability issues.
We have:
Exclusively licensed the IP from U of FL
Filed 4 additional patents
Raised Series A financing led by Broadview Ventures
Completed Phase I with our lead compound, GT-001, in record time, 18 months on $4M
SAD study in healthy volunteers:
-No observed safety or tolerability issues though the highest dose
-No systemic drug exposure
-Robust and dose dependent increase in satiety and reduction in hunger
We are in the late stages of negotiations to finance our lead program & seek to raise a $10m financing & to establish a strategic partnership to advance our preclinical pipeline
We have:
Exclusively licensed the IP from U of FL
Filed 4 additional patents
Raised Series A financing led by Broadview Ventures
Completed Phase I with our lead compound, GT-001, in record time, 18 months on $4M
SAD study in healthy volunteers:
-No observed safety or tolerability issues though the highest dose
-No systemic drug exposure
-Robust and dose dependent increase in satiety and reduction in hunger
We are in the late stages of negotiations to finance our lead program & seek to raise a $10m financing & to establish a strategic partnership to advance our preclinical pipeline
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Minnesota
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Metabolic Diseases
Lead Product in Development:
GT-001
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3+
Speaker
